The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Perioperative trastuzumab and pertuzumab in combination with FLOT versus FLOT alone for HER2 positive resectable esophagogastric adenocarcinoma: Petrarca—A phase II trial of the German AIO.
 
Ralf Hofheinz
Honoraria - Lilly
 
Gerrit zur Hausen
Honoraria - Celgene
Travel, Accommodations, Expenses - Celgene
 
Kersten Borchert
No Relationships to Disclose
 
Albrecht Kretzschmar
Honoraria - Roche
Consulting or Advisory Role - Roche
Speakers' Bureau - Roche
 
Matthias Philip Ebert
No Relationships to Disclose
 
Thomas Jens Ettrich
Honoraria - Celgene
Consulting or Advisory Role - Bayer; Bayer; Merck Serono; Merck Serono; Novartis; Sanofi; Sanofi; Sirtex Medical
Research Funding - Baxalta/Shire
Travel, Accommodations, Expenses - Ipsen
 
Michael Koenigsmann
Honoraria - Celgene; Novartis
Consulting or Advisory Role - Gilead Sciences; Novartis
Travel, Accommodations, Expenses - Novartis
 
Georg Martin Haag
Consulting or Advisory Role - Lilly; Nordic Bioscience; Pfizer; Roche; Sanofi; Taiho Pharmaceutical
Research Funding - Nordic Bioscience (Inst); Taiho Pharmaceutical (Inst)
Travel, Accommodations, Expenses - Amgen; Celgene; Ipsen
 
Volker A. Hagen
Honoraria - Amgen; Bristol-Myers Squibb; Celgene; Pfizer; Roche
Consulting or Advisory Role - Celgene; Roche
Travel, Accommodations, Expenses - Johnson & Johnson; Pfizer; Roche
 
Thomas Hoehler
No Relationships to Disclose
 
Nils Homann
Consulting or Advisory Role - Amgen; Celgene; Lilly; Roche; Sanofi
 
Hendrik Kroening
No Relationships to Disclose
 
Peter Reichardt
Honoraria - Amgen; Bayer; GlaxoSmithKline; Lilly; Novartis; Pfizer; PharmaMar
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Clinigen Group; GlaxoSmithKline; Lilly; Novartis; Pfizer; PharmaMar
Research Funding - Novartis (Inst)
 
Michael Rieger
No Relationships to Disclose
 
Christian Teschendorf
No Relationships to Disclose
 
Eray Goekkurt
No Relationships to Disclose
 
Udo Lindig
No Relationships to Disclose
 
Wolff H. Schmiegel
Consulting or Advisory Role - 4SC; AiCuris; Amgen; Apceth; AstraZeneca; Indivumed; Merck Serono; Roche
Research Funding - see link: http://www.medunikkh.de/aerzte/studien/ (Inst)
Patents, Royalties, Other Intellectual Property - Biomarker für die Diagnose von Pankreaskrebs Internationale Patentanmeldung PCT/DE2007/002174 Anmelder: Prof. Dr. Schmiegel, Prof. Dr. S. Hahn, Prof. Dr. H.E. Meyer, Dr. Sitek, Dr. K. Stühler, Dr. Bence-Sipos, Prof. Dr. Klöppel, Dr. Alkatout; Biomarker für hepatische Fibrose Patentanmeldung Deutschland: DE 10 2006 048249.2. Internationale Patentanmeldung PCT/DE 2007001427 Anmelder: Prof. Dr. W. Schmiegel, Dr. C. Mölleken, Dr. Bence-Sipos, Prof. Dr. Klöppel, Prof. Dr. H.E. Meyer, Dr. K. Stühl; Buproprion – Verwendung von Bupropion in Arzneimittel zur Behandlung von Hepatitis C Patentanmeldung Deutschland: DE 10 2004 063 132.8-41 Anmelder: Prof. Dr. W. Schmiegel; Diagnoseverfahrung und Verwendung von MicroRNA Patentanmeldung Deutschland 10 2010 046 866.5 Anmelder: Dr. A. Baraniskin, Prof. Dr. U. Schlegel, Prof. Dr. W. Schmiegel, PD Dr. R. Schroers; Immunoscreening of the Extracellular Proteome of Colorectal Cancer Cells Patentanmeldung USA US 61/176,353 Anmelder: Prof. Dr. W. Schmiegel, Prof. Dr. H.E. Meyer; Lösliches Cadherin 17 für die Diagnose und Risikostratifizierung von Darmtumor und Darmkrebs Internationale Patentanmeldung: PCT/DE2008/001220 Anmelder: Hanna Diehl, Dr. Kai Stühler, Prof. Dr. H. E. Meyer, Dr. S. Klein-Scory, PD Dr. I. Schwarte-Waldho; Pantumormarker Patentanmeldung Deutschland 10 2011 108 254.2 Anmelder: Prof. Dr. W. Schmiegel, Prof. Dr. Stephan Hahn, Dr. Alexander Baraniskin; Statine/HMG-CoA Reduktase Hemmer zur Herstellung von Mitteln, die sich zur Primär- und Sekundärprävention sowie zur Behandlung von hyperplastischen oder dysplastischen Dickdarmpolypen eignen. Patentanmeldung Deutschland DE 10 2004 036 907.0-41 Anmelder:
Travel, Accommodations, Expenses - Abbott; Deutscher Ärzteverlag; Dres. Schlegel + Schmidt; Falk Foundation; GSB Pharma; Labor Berlin-Charité Vivantes Services GmbH; Lilly; MedCongress; Merck Serono; Miami Cancer Institute; Pfizer; Roche; Sanofi; Siemens Healthineers
 
Claudia Pauligk
No Relationships to Disclose
 
Salah-Eddin Al-Batran
Consulting or Advisory Role - Bristol-Myers Squibb; Celgene; Lilly; Merck; Roche; SERVIER
Speakers' Bureau - Celgene; Lilly; Nordic Bioscience; Roche
Research Funding - Celgene; Hospira; Lilly; Medac; Novartis; Roche Pharma AG; Vifor Pharma